# Arcturus Therapeutics Holdings Inc.: overview ARCT · Nasdaq · CIK 1768224 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/arct.md) · [Financials](/companies/arct/financials.md) · [Filings](/companies/arct/filings.md) · [Insiders](/companies/arct/insiders.md) Latest reported revenue: [$3.0m](/filings/0001193125-26-338090.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-338090). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [41.7](/filings/0001193125-25-275758.md) | [22.8 d](/filings/0001193125-26-088391.md) | [29.4](/filings/0001193125-26-211943.md) | [28.3](/filings/0001193125-26-338090.md) | [17.2](/filings/0001193125-25-275758.md) | [7.2 d](/filings/0001193125-26-088391.md) | [2.1](/filings/0001193125-26-211943.md) | [3.0](/filings/0001193125-26-338090.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(25.8%)](/filings/0001193125-25-275758.md) | [(146.7%) d](/filings/0001193125-26-088391.md) | [(57.3%)](/filings/0001193125-26-211943.md) | [(41.0%)](/filings/0001193125-26-338090.md) | [(96.3%)](/filings/0001193125-25-275758.md) | [(435.1%) d](/filings/0001193125-26-088391.md) | [(1403.7%)](/filings/0001193125-26-211943.md) | [(863.3%)](/filings/0001193125-26-338090.md) | | Net margin | % | [(16.6%)](/filings/0001193125-25-275758.md) | [(131.8%) d](/filings/0001193125-26-088391.md) | [(47.9%)](/filings/0001193125-26-338090.md) | [(32.4%)](/filings/0001193125-26-338090.md) | [(78.4%)](/filings/0001193125-25-275758.md) | [(404.1%) d](/filings/0001193125-26-088391.md) | [(1308.3%)](/filings/0001193125-26-338090.md) | [(803.8%)](/filings/0001193125-26-338090.md) | | Diluted EPS | $ per share | [(0.26)](/filings/0001193125-25-275758.md) | not reported | [(0.52)](/filings/0001193125-26-211943.md) | [(0.34)](/filings/0001193125-26-338090.md) | [(0.49)](/filings/0001193125-25-275758.md) | not reported | [(0.95)](/filings/0001193125-26-211943.md) | [(0.84)](/filings/0001193125-26-338090.md) | | Free cash flow | $m | [(23.8) d](/filings/0001193125-25-275758.md) | [(0.3) d](/filings/0001193125-26-088391.md) | [(35.3)](/filings/0001193125-26-211943.md) | [(5.8) d](/filings/0001193125-26-338090.md) | [(17.3) d](/filings/0001193125-25-275758.md) | [(16.3) d](/filings/0001193125-26-088391.md) | [(19.4)](/filings/0001193125-26-211943.md) | [(19.9) d](/filings/0001193125-26-338090.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.4](/filings/0000950170-24-031156.md) | [206](/filings/0000950170-25-034787.md) | [167](/filings/0001193125-26-088391.md) | [152](/filings/0001193125-26-088391.md) | [82.0](/filings/0001193125-26-088391.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1641.3%)](/filings/0000950170-24-031156.md) | [5.9%](/filings/0000950170-25-034787.md) | [(46.9%)](/filings/0001193125-26-088391.md) | [(62.8%)](/filings/0001193125-26-088391.md) | [(93.0%)](/filings/0001193125-26-088391.md) | | Net margin | % | [(1648.0%)](/filings/0000950170-24-031156.md) | [4.5%](/filings/0000950170-25-034787.md) | [(17.8%)](/filings/0001193125-26-088391.md) | [(53.1%)](/filings/0001193125-26-088391.md) | [(80.2%)](/filings/0001193125-26-088391.md) | | Diluted EPS | $ per share | [(7.74)](/filings/0000950170-24-031156.md) | [0.35](/filings/0000950170-25-034787.md) | [(1.12)](/filings/0001193125-26-088391.md) | [(3.00)](/filings/0001193125-26-088391.md) | [(2.40)](/filings/0001193125-26-088391.md) | | Free cash flow | $m | [(138)](/filings/0000950170-24-031156.md) | [24.3](/filings/0000950170-25-034787.md) | [(21.0)](/filings/0001193125-26-088391.md) | [(60.4)](/filings/0001193125-26-088391.md) | [(74.5)](/filings/0001193125-26-088391.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/arct/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2021-08-11 | [Ultragenyx Pharmaceutical Inc.](/insiders/1515673.md) | Director | Sale (S) | 75,000 | $45.83 | $3.4m | [Form 4](/filings/0001209191-21-051182.md) | | 2021-08-10 | [Ultragenyx Pharmaceutical Inc.](/insiders/1515673.md) | Director | Sale (S) | 725,000 | $55.44 | $40.2m | [Form 4](/filings/0001209191-21-051182.md) | | 2020-12-09 | [Ultragenyx Pharmaceutical Inc.](/insiders/1515673.md) | Director, 10% owner | Sale (S) | 357,745 | $94.97 | $34.0m | [Form 4](/filings/0001209191-20-062733.md) | | 2020-12-08 | [Ultragenyx Pharmaceutical Inc.](/insiders/1515673.md) | Director, 10% owner | Sale (S) | 442,255 | $105.54 | $46.7m | [Form 4](/filings/0001209191-20-062733.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $22.2m | 3,303,640 | | Unchanged | | [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $19.5m | 2,901,635 | | Added +132,117 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $17.6m | 2,614,012 | | Added +731 | | [Sumitomo Mitsui Trust Group, Inc.](/funds/1475365.md) | 2026-06-30 | $13.2m | 1,963,123 | | Reduced −325,812 | | [Amova Asset Management Americas, Inc.](/funds/1480751.md) | 2026-06-30 | $13.1m | 1,960,458 | | Reduced −328,477 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.5m | 1,114,956 | | Added +7,936 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $7.3m | 1,091,137 | | Added +9,353 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $6.4m | 951,575 | | Reduced −26,347 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.7m | 693,660 | | Added +32,732 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $4.5m | 675,014 | | Added +513,736 | ## Recent filings [All 392 filings](/companies/arct/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-23 | 16:11 ET | [8-K](/filings/0001193805-26-001277.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-001277 | | 2026-08-25 | 06:00 ET | [8-K](/filings/0001193805-26-001130.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-001130 | | 2026-08-06 | 16:19 ET | [10-Q](/filings/0001193125-26-338090.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338090 | | 2026-08-06 | 16:06 ET | [8-K](/filings/0001193805-26-001039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193805-26-001039 | | 2026-07-02 | 07:05 ET | [8-K](/filings/0001193805-26-000910.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-000910 | | 2026-06-05 | 17:20 ET | [8-K](/filings/0001193805-26-000770.md) | 5.07 Shareholder vote results | 0001193805-26-000770 | | 2026-05-07 | 16:14 ET | [10-Q](/filings/0001193125-26-211943.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211943 | | 2026-05-07 | 16:08 ET | [8-K](/filings/0001193805-26-000573.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193805-26-000573 | | 2026-04-24 | 16:05 ET | [DEF 14A](/filings/0001193805-26-000507.md) | Proxy statement, period 2026-06-05 | 0001193805-26-000507 | | 2026-03-03 | 16:34 ET | [10-K](/filings/0001193125-26-088391.md) | Annual report, period 2025-12-31 | 0001193125-26-088391 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-088391.md), filed Mar 3, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e682e1c9-1a4d-49bf-9106-8f457666430e) ## About the filer - CIK: 1768224 - Tickers: ARCT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 06:06 ET. No prices; not investment advice.